TriLink BioTechnologies et Lonza signent un contrat de licence et dapprovisionnement non exclusif pour la technologie de capsulage dARNm CleanCap
MRVI Stock | USD 5.92 0.30 5.34% |
Under 61% of all Maravai Lifesciences' traders are looking to take a long position. The analysis of overall sentiment of trading Maravai Lifesciences Holdings stock suggests that some investors are interested at this time. Maravai Lifesciences' investing sentiment shows overall attitude of investors towards Maravai Lifesciences Holdings.
Maravai |
TriLink BioTechnologies , une socit de Maravai LifeSciences et fournisseur mondial de ractifs et de services dans le dom
Read at businesswire.com
Maravai Lifesciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Maravai Lifesciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Maravai Lifesciences Fundamental Analysis
We analyze Maravai Lifesciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maravai Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maravai Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Maravai Lifesciences is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Maravai Lifesciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Maravai Lifesciences stock to make a market-neutral strategy. Peer analysis of Maravai Lifesciences could also be used in its relative valuation, which is a method of valuing Maravai Lifesciences by comparing valuation metrics with similar companies.
Peers
Maravai Lifesciences Related Equities
IMVT | Immunovant | 5.78 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
AKRO | Akero Therapeutics | 3.24 | ||||
HRMY | Harmony Biosciences | 2.64 | ||||
DNLI | Denali Therapeutics | 1.94 | ||||
ABUS | Arbutus Biopharma | 1.76 | ||||
ARQT | Arcutis Biotherapeutics | 1.74 | ||||
RARE | Ultragenyx | 1.63 | ||||
HALO | Halozyme Therapeutics | 1.42 | ||||
LEGN | Legend Biotech | 1.29 | ||||
ASND | Ascendis Pharma | 1.28 | ||||
ARGX | Argenx NV | 1.22 | ||||
FOLD | Amicus Therapeutics | 0.91 | ||||
INCY | Incyte | 0.87 | ||||
CYTK | Cytokinetics | 0.38 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
PTGX | Protagonist Therapeutics | 0.27 | ||||
INSM | Insmed | 0.26 | ||||
KRYS | Krystal Biotech | 0.20 | ||||
ROIV | Roivant Sciences | 0.08 | ||||
AGIO | Agios Pharm | 0.74 | ||||
ALEC | Alector | 0.78 |
Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Transaction History View history of all your transactions and understand their impact on performance | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |